Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03959891
Title AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

Her2-receptor negative breast cancer

Therapies

Fulvestrant + Ipatasertib + Palbociclib

Ipatasertib

Fulvestrant + Ipatasertib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.